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Abstract: We evaluated 6 different porcine zona pellucida (PZP) preparations used as a 
single-shot vaccine for multiyear contraception of captive white-tailed deer (Odocoileus vir-
ginianus). The study compared 2 PZP preparation technologies from ImmunoVaccine Tech-
nologies™ (IVT) and National Wildlife Research Center (NWRC) over a 7-year period. The 
study compared both the use of oil in an emulsion and in suspension delivery, as well as 
replacement of the oil with an alum adjuvant. The study demonstrated that the oil emulsion 
adjuvant provided the longest lasting response. PZP isolated by the IVT provides a longer-
lasting response than the preparation used by NWRC. The SpayVacTM and IVT-PZP vaccines 
presented in an emulsion form with AdjuVac™ produce a single-shot immunocontraceptive 
vaccine lasting up to 7 years.
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Immunocontraceptive vaccines prevent 
conception by stimulating production of anti-
bodies that bind with and neutralize proteins 
or hormones essential for reproduction (Cur-
tis et al. 2008, Miller et al. 2008). Porcine zona 
pellucida (PZP) vaccines prepared using zonae 
pellucida isolated from pig ovaries are one of 
the most studied immunocontraceptive vac-
cines in wildlife. The zona pellucida is a cel-
lular glycoprotein layer surrounding the mam-
malian oocyte. During fertilization, sperm bind 
to receptors on the outer surface of the oocyte 
and penetrate the zona pellucida. Anti-PZP an-
tibodies block sperm binding and penetration 
into the ovum and may also interfere with fol-
licle maturation and ovulation (Dunbar 1989, 
Aitken et al 1996). Females treated with PZP 
vaccines typically experience multiple infertile 
estrous cycles throughout the breeding season 
(Killian and Miller 2000, Miller and Killian 2000, 
Miller et al. 2000). PZP vaccines have been used 
to contracept feral horses (Equus caballus; Kir-
patrick et al. 1990, Kirpatrick et al. 1992), white-
tailed deer (Odocoileus virginianus; Curtis et al. 
2007, Killian et al. 2008, Rutberg and Naugle 
2008), coyotes (Canis latrans; Miller et al. 2006), 
domestic sheep (Ovis aries; Stoops et al. 2006), 
and captive exotic species (Frank et al. 2005).
Based on the encouraging results of early 
investigations, we began studies with the PZP 
vaccine in white-tailed deer during 1992. We 
hoped to develop a single-shot contraceptive 
vaccine that was safe for the animals and had 
multiyear effi  cacy. White-tailed deer were then, 
as they are now, of interest as a target species 
because of inadequate control methods avail-
able to deal with dense urban and suburban 
deer populations in the northeastern United 
States (Hussain et al. 2007, Bissonett ee et al. 
2008, DeNicola and Williams 2008, Mastro and 
Conover 2008, Ng et al. 2008). 
In an early study, we immunized white-tailed 
deer with a 1-ml injection containing 500-μg 
PZP in Freund’s Complete Adjuvant™ (FCA) 
followed by multiple booster injections, each 
with 1-ml injection containing 300-μg PZP in 
Freund’s Incomplete Adjuvant™ (FIA). In the 
fi rst year, the prime dose was given in August 
and 2 boosts were given in September and Oc-
tober. In November, the does were exposed to 
bucks. In the second year, does were given 1 or 
2 boosts, depending on their current PZP titer. 
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We continued the study for 4 more years with-
out additional boosts. The does exhibited 100% 
contraception the fi rst year, 89% over 3 years, 
and 76% over 6 years (Miller and Killian 2000). 
Given the multiple injections and the high dose 
of PZP required to induce infertility, we rec-
ognized that this approach was not practical 
for fi eld applications. In a later fi eld study, we 
showed that a prime and boost of 100 ug of PZP 
emulsifi ed in FCA and FIA could provide mul-
tiyear contraception (Curtis et al. 2008).
Few studies have reported that a single-injec-
tion vaccine can provide immunization with ef-
fectiveness up to 2 years (Fraker et al. 2002, Liu 
et al. 2005, Locke et al. 2007, Turner et al. 2007, 
Rutberg and Naugle 2008). In mice, a single in-
jection with a vaccine containing infl uenza vi-
ral peptides and adjuvant (Adjumer®) in mice 
caused antibody titers to increase gradually 
up to 6 months, but titers began to decline at 
9 months (Payne et al. 1995). Their study sug-
gested that for infertility to be achieved with a 
single injection, the vaccination would need to 
be given months before the onset of reproduc-
tive activity (i.e., the rut period) so that an ad-
equate titer level could develop for contracep-
tion to occur. 
Adjuvants are critical in vaccines for the de-
velopment of high antibody titers in response 
to vaccination. Our work on a new adjuvant be-
gan in 1998 aft er learning that the U.S. Food and 
Drug Administration (FDA) would not approve 
the use of vaccines containing FCA because this 
adjuvant was associated with signifi cant reac-
tions at the site of injection. Consequently, we 
developed a new oil-based adjuvant called 
AdjuVac, containing <200 μg of killed Mycobac-
terium avium per dose. M. avium is a common 
nonpathogenic bacterium to which most wild-
life and domestic animals worldwide have been 
exposed. 
The experiments described in the current pa-
per represent the last phase of the study con-
ducted with the PZP vaccine in white-tailed 
deer. The objectives of the study was to com-
pare the eff ectiveness of 6 diff erent single shot 
vaccine formulations, containing diff erent PZP 
preparations and diff erent adjuvants or deliv-
ery systems.
Methods
Deer Research Center at Pennsyl-
vania State University 
White-tailed deer used in this study were 
born, raised, and maintained at the Pennsylvania 
State University (PSU) Deer Research Center. The 
original source of animals for the PSU deer herd 
was the free-roaming white-tailed deer popu-
lation from central Pennsylvania. During our 
study, the PSU deer facility encompassed 54 ha 
of natural forest habitat and was divided into 9 
outdoor paddocks ranging in size from 0.1 to 
1.5 ha. Vegetation on the open areas consisted 
of a mixture of clover and orchard grasses, but 
most of the land was covered with dense east-
ern deciduous forest that had litt le understory 
vegetation. Deer were kept at a density of 25 
to 37 animals per ha. During the nonbreeding 
season, treated female deer were isolated from 
males. To test vaccine contraceptive effi  cacy, 4 
bucks of proven sire ability were confi ned with 
the does each year from the fi rst week of No-
vember through the end of the following Feb-
ruary.
PZP vaccine preparations
The heat-soluble PZP preparation used for the 
PZP was prepared by Dr. Irwin Liu (University 
of California at Davis) following the method 
described by Dunbar and Raynor (1980). PZP 
was provided to NWRC in phosphate buff ered 
saline (PBS ) buff er at a protein concentration of 
1 mg/ml. It was used in either a 200-μg or 500-
μg protein dose prepared as an emulsion with 
AdjuVac for administration in a 1-ml volume. 
This preparation will henceforth be referred to 
as NWRC-PZP.
ImmunoVaccine Technologies™ 
(IVT) PZP vaccine preparations 
ImmunoVaccine Technologies™ (IVT) of 
Halifax, Nova Scotia, Canada, developed the 
IVT-PZP preparation using the Yurewicz et al. 
(1983) procedure to isolate zona. This method 
is similar to that described by Dunbar and 
Raynor (1980). The IVT procedure consisted of 
homogenizing the ovaries in Tris buff er by pas-
sage through a commercial meat grinder. The 
resulting oocytes were cleared from cellular de-
bris by successive passages of the ground tissue 
through a series of nylon screens of decreas-
ing pore size. The oocytes were then passed 
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through a homogenizer to release the zona pel-
lucida. We emulsifi ed this PZP with AdjuVac to 
create the IVT-PZP vaccine. We used SpayVac 
(an IVT-PZP preparation encapsulated in li-
posomes; Brown et al. 1997) in 3 other vaccine 
preparations. These were SpayVac emulsifi ed 
with AdjuVac, lypohilized SpayVac suspended 
in AdjuVac, and SpayVac mixed with alum as 
the adjuvant. 
 Experimental design
We divided 30 deer into 6 treatment groups 
of 5 does each (Table 1). The fi rst 4 treatment 
groups were vaccinated with variations of the 
IVT-PZP preparation. Group 1 was vaccinated 
with SpayVac (IVT-PZP encapsulated in lipo-
somes) suspended in AdjuVac. Group 2 was vac-
cinated with IVT-PZP (without the liposomes) 
suspended in AdjuVac. Group 3 was vaccinated 
with lyophilized SpayVac suspended in Adju-
Vac. Group 4 received SpayVac combined with 
alum. Lyophilized (freeze-dried) vaccine used 
in Group 3 evaluated whether a suspension 
would produce a long-lasting contraceptive 
eff ect like that seen with the emulsion in the 
standard vaccine preparations. The SpayVac in 
alum used in Group 4 was intended to evaluate 
the utility of alum suspension as an adjuvant 
for producing long-term contraception.
All IVT-PZP-treated deer were vaccinated 
with 200 μg of PZP that contained approxi-
mately 35% protein. The IVT-PZP preparation 
contained some precipitate that became part of 
the vaccine preparation. Groups 5 and 6 were 
vaccinated with 200-μg and 500-μg doses, re-
spectively, of NWRC-PZP as measured by Low-
ry assay. Vaccines were prepared by producing 
a 1:1 emulsion volume:volume with AdjuVac. 
We administered all PZP vaccine formula-
tions in mid-July 2000. We took 10 ml of blood 
from does in all groups except for Group 2, 
which was vaccinated during July 2001. Fawn-
ing data were available for untreated does ex-
posed to bucks in the Penn State herd during 
each year of study. While these does were not 
sham-treated, they were handled in the sum-
mer and fall, as were the treated does, when 
they received health vaccinations. We consid-
ered the fawning rates of the untreated does to 
represent normal fertility rates for does in the 
Penn State herd.
Laboratory methods
We collected 10 ml of blood by jugular ve-
nipuncture from the study deer in July, Sep-
tember, November, and February. We used the 
sample to determine antibody titers, progester-
one levels, and pregnancy-specifi c protein B in 
samples collected in February. Anti-PZP titers 
for groups using IVT-PZP and the NWRC-PZP 
200 μg/dose as the antigen were determined 
by ELISA at the IVT laboratories. This method 
reports the titer as a percentage of a standard 
rabbit anti-PZP titer, which is considered 100% 
(Brown et al. 1997). 
Anti-PZP titers for the NWRC-PZP 500 μg/
dose vaccine were measured, using ELISA at 
the NWRC laboratories. Titers were calculated 
as the last serial dilution in which the treated 
sample was at least twice the absorbance of the 
pretreated sample of the same animal. In the 
NWRC laboratory method to determine anti-
Table 1. Experimental design defi ning the nature of the vaccine treatments and adjuvants.
Groups 1–4 represent PZP produced by IVT mixed with diff erent adjuvant preparations. Groups 4 
and 5 represent 200 and 500 μg of PZP from NWRC, both made into an emulsion.
Group Vaccine Treatment Liposomes Adjuvant Adjuvant-Vaccine Mixture
1 IVT-PZP(200 μg)—SpayVac Yes AdjuVac Emulsion
2 IVT-PZP(200 μg) No AdjuVac Emulsion
3 IVT-PZP(200 μg)—SpayVac-lyophilized Yes AdjuVac Suspension
4 IVT-PZP(200 μg)—SpayVac Yes Alum Suspension
5 NWRC-PZP(200 μg) No AdjuVac Emulsion
6 NWRC-PZP(500 μg) No AdjuVac Emulsion
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body titers, 100 ng of PZP antigen was placed 
in each well of a micro-titer plate. Sea BlockTM 
(Pierce Chemical, Rockford, Ill.) was used to 
prevent binding of antibodies to the plastic in 
the ELISA plate. Deer serum was serially dilut-
ed from 1:1,000 to 1:128,000 in PBS containing 
Sea Block. Antibodies in the deer serum to the 
native PZP antigen on the plate were directed 
with the following linkages: deer anti-PZP 
binds to PZP on the plate, rabbit anti-deer IgG 
binds to the deer IgG, goat anti-rabbit-peroxi-
dase binds to the rabbit IgG. Tetramethylben-
zidine was used to develop the color, and 2M 
H2SO4 was used to stop the reaction. The color 
intensity of the sample was read at 450 nm with 
a Dynatech MR 5000 ELISA plate reader. 
 Plasma progesterone levels were assayed by 
the coat-a-tube RIA method (Diagnostic Prod-
ucts, Los Angeles, Calif.), following the manu-
facturer’s recommended procedure. Assays 
for Pregnancy-Specifi c Protein B (PSPB) were 
performed by ELISA on samples submitt ed to 
BioTracking LLC (Moscow, Ida.).
Behavioral observations
We monitored estrous cycles in deer to deter-
mine the frequency of estrus and to learn about 
the mechanism of multiyear contraception. 
To determine when the does were in estrus, 
trained observers monitored the behavior of 
bucks toward the treated does. Three observa-
tion periods of >30 minutes each were sched-
uled daily from November 7 through February 
12, followed by 2 periods daily until February 
28. Behavioral activity by the buck was record-
ed on an observation sheet for a range of activi-
ties, including sniffi  ng genitalia, pursuit of the 
female, aggressive guarding, and copulation 
(Killian and Miller 2000).
Ultrasonography and fawning data
We performed trans-rectal ultrasonography 
in late January or early February of each year 
to determine which does were in the fi rst tri-
mester of gestation. Blood drawn on the same 
day was tested for progesterone concentration 
and PSPB. From May through September, does 
were observed daily for evidence of fawning. 
We recorded fawning dates and the number 
of fawns born and compared them to observa-
tions on behavioral estrus to estimate the date 
of conception. 
Defi nitions of contraception and 
fertility
Does that were exposed to bucks and showed 
signs of estrus, but did not fawn were consid-
ered contracepted or infertile. Does in each 
group were monitored for contraceptive lon-
gevity and remained on the study until they 
had twins. Does >2 years old and having 1 fawn 
were assumed to be sub-fertile because this is 
less than the average fawning rate of 2 fawns in 
untreated does in the Penn State herd.
Results
Contraception 
The average fawning rate of the Penn State 
herd for 84 untreated does from 2001 through 
2007 was 1.8 fawns per doe, with an average 
doe age of 4 years (Table 2). Number of fawns 
born varied with does age. For 2-year-olds, the 
Table 2. Fawning data for untreated does in the Penn State University deer herd during the same years that the 
contraceptive trial was conducted. 
Year % infertile n Average doe age
% does with 1 
fawn
% does with 
2 or more 
fawns
Average 
fawns/doe
1 0   9 4.0 67   33  1.4
2 0 26 3.1 23   77  1.8
3 0   8 4.7 13   87  2.0
4 0 10 4.2 20   80  2.0
5 0 13 4.2   0 100  2.0
6 0   8 4.6 13   87  1.9
7 0 10 4.5 20   80  1.8
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average number of fawns born was 1.7. For 
does >2 years old, the average number of fawns 
born was 2.0. 
Groups 1 and 2, which combined SpayVac or 
IVT-PZP into an emulsion with AdjuVac, had 
the longest contraceptive eff ect, with 80% of 
the deer contracepted for 5 to 7 years (Table 3). 
Unfortunately, Group 1 was terminated aft er 
5 years because of lack of funding, with 80% 
of the treated deer still contracepted. One doe 
in Group 2 had twins in year three and was 
dropped from the study. In year fi ve, 1 of the 4 
remaining does in this group had a single fawn, 
reducing the rate of contraception to 60%. How-
ever, because the birth of a single fawn did not 
represent a complete breakthrough from im-
munological contraception, all 4 does were kept 
for another year. In years six and seven, the doe 
that had a fawn in year fi ve did not fawn, re-
storing the contraception rate to 80% (Table 2). 
Does in Group 3 were all contracepted in 
the fi rst year, one of the 4 does conceived the 
second year, two of the 4 does had fawns dur-
ing the third year, and all fawned during the 
fourth year (Table 3). Consequently, this group 
was dropped from the study at the end of year 
four. 
Four of the 5 does in Group 4 each had 1 
fawn in the fi rst year (Table 3). Consequently, 
this group was removed from the study aft er 
the fi rst year. Groups 5 and 6 received 200 μg 
and 500 μg of NWRC-PZP, respectively, in an 
emulsion made with AdjuVac. For Group 5, 1 
doe had 2 fawns the fi rst year, for an 80% con-
traception rate (Table 3). However, because all 
5 does produced 2 fawns in the second year, 
Group 5 (200 μg of NWRC-PZP) was subse-
quently removed from the study. Does receiv-
ing 500 μg of PZP were 100% contracepted the 
fi rst year, but 4 of 5 does produced fawns the 
second year (Table 3). This 20% contraception 
rate remained until year fi ve, when the remain-
ing doe produced 2 fawns.
The number of fawns that could be produced 
by the diff erent groups, had they not be contra-
cepted, was estimated from the average fawn-
ing rates of untreated does in the herd during 
the same years. This estimate of fecundity for 
the 5 years when Group 1 was on the study was 
46 fawns compared to 64 fawns for 7 years of 
study with Group 2 (Table 3). Considering that 
actual numbers of fawns produced for these 2 
groups during the periods of study were 2 and 
4 respectively, fecundity was reduced greater 
than 90% by the vaccines containing IVT-PZP. 
 Antibody titers 
Comparing the anti-PZP titers of all of the 
groups, Group 1 (SpayVac; Figure 1a) had the 
greatest initial immune response of all groups, 
with a peak antibody titer at 18 months and a 
titer of 80 to 100% of the rabbit standard dur-
ing the fi rst 2 years. Although the titer began to 
drop aft er 18 months, it was sustained at 40% 
to the end of the 5-year study. The rise in anti-
body titer for Group 2 IVT-PZP (Figure 1b) was 
slower than that observed for Group 1, but by 
year three, both groups had similar titers. The 
antibody response patt erns for Group 2, and to 
a lesser extent for Groups 1 and 3, included a 
self-boosting of titers, which was evident as ti-
ters increased without additional antigen injec-
tions (Figures 1a and 1b). Notably, for Groups 
1 and 2, the high rates of contraception were 
maintained even with lower titers in years four 
through seven. 
Deer in Group 3 that were given freeze-dried 
SpayVac suspended in AdjuVac, were 100% 
contracepted in the fi rst year, but contracep-
tion rates dropped off  to 75%, 50%, and 0% in 
years two, three, and four, respectively (Table 
3). Titers for Group 3 were high through year 
two, but dropped in years three and four (Fig-
ure 1c), indicating that freeze-dried SpayVac in 
suspension was less eff ective for long-term con-
traception than the non-freeze-dried emulsion 
form of SpayVac. SpayVac with alum adjuvant 
produced a large variation in the immune re-
sponses, and only 1 doe produced a good im-
mune response (Figure 2a).
Titers for Group 5, (200-μg NWRC-PZP mixed 
with AdjuVac) were relatively high in the fi rst 
year (Figure 2a), with an 80% contraception 
rate. However, average titers dropped dramati-
cally in year two, and all of the does conceived. 
Antibody titers determined for Group 6, treat-
ed with (500-μg NWRC-PZP mixed with Adju-
Vac™) were very high immediately aft er injec-
tion, but declined over the next 2 years (Figure 
2b). In contrast to the IVT-PZP used in Groups 
1 and 2 (Figures 1a and 1b), the NWRC-PZP-
treated does in Groups 5 and 6 did not appear 
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Figure 1a. Group 1: Ab 
titer (PZP Lipo06sp). 
SpayVac as an emul-
sion with AdjuVac. 
Figure 1b. Group 2: Ab titer 
(PXPb200spwpd). IVT-PZP 
as an emulsion with Adju-
Vac.
Figure 1, a–d. Each group represents a different PZP with different adjuvant preparations and delivery 
methods.  Antibody titers are presented as a percentage of a 100% anti-PZP rabbit standard. July 2000 
to February 2006 represents the month-years post treatment throughout the study. The graph ends at the 
point that all deer in the group became pregnant and the group was dropped from the study.  Each data 
point represents the mean ± SE. 
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Figure 1c. Group 3: 
SpayVac, freeze-dried, as a 
suspension in AdjuVac. 
Figure 1d. Group 4: SpayVac 
absorbed onto alum.
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to stimulate self-boosting, and the decreasing 
of antibody titers (Figures 2a and 2b) resulted 
in greater pregnancy rates in subsequent years 
(Table 3).
Behavioral observations
PZP-treated deer had multiple estrous cycles 
every year of the 5-year study, with the multi-
cycling ceasing only when they became preg-
nant. The number of estrus events for all PZP-
treated deer ranged from 1.5 to 3.0 per season, 
with an average breeding season length of 150 
days. This compares to 0.2 to 0.5 estrus events 
for does in the untreated herd and an average 
breeding period of 42 days per season. The 4 
does in IVT-PZP Group 2 averaged 1.75 estrus 
events in year seven of the trial, demonstrating 
that cycling was still occurring, although none 
of the does had fawns. 
Progesterone and pregnancy-
specifi c protein B determinations 
Blood samples taken from deer anually in 
July, September, November, and February were 
assayed for serum progesterone concentra-
tions. Despite the fact that the PZP-treated deer 
showed signs of estrus and breeding behav-
iour during November and December, the only 
consistent elevation in serum progesterone 
observed was in the February blood samples 
of SpayVac Group 1, IVT-PZP Group 2, and 
NWRC-PZP 500-μg Group 6 (Figures 3a, 3b and 
3c). This consistent increase in serum proges-
terone in February in the PZP-treated does was 
not associated with pregnancy.
Blood serum was taken from 6 adult, prov-
en-breeder does that were not bred during the 
2006–2007 breeding season. Because these un-
bred, untreated does showed a similar eleva-
tion of serum progesterone in February (5.6 ± 
0.4 SE), we concluded that this elevation of pro-
gesterone may be normal for cycling, nonpreg-
nant does as they return to an anestrous state in 
the nonbreeding season.
In contrast to serum progesterone concen-
trations, PSPB levels with a mean of 0.3 (non-
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Figure 2 a–b. Groups 5 and 6 represent 2 concentrations of the NWRC-PZP vaccine serial dilution end 
point. July 2000 is the date of the vaccination, with July 2000 to February 2006 as the months and years of 
post-treatment throughout the study. The graph ends at the point that all deer in the group became preg-
nant, and the group was dropped from the study. Each data point represents the mean (±SE).
Figure 2a. Group 5: 
200 μg of NWRC-
PZP presented as 
an emulsion with Ad-
juVac, antibody titer 
presented as a per-
centage of a rabbit 
standard as 100%.
Figure 2b. Group 6: 
500 μg of NWRC-
PZP presented as 
an emulsion with 
AdjuVac antibody 
titer presented as a 
1/1000 –1/256,000 
serial dilution end 
point. 
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pregnant values >1.0) were well-correlated 
with ultrasound and fawning results. The PSPB 
levels were correlated with fawning (r = 0.83, P 
<0.0001). 
Injection-site reactions
There were no injection-site reactions in any 
of the treatment groups observed throughout 
the study.  
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Figure 3 a–c. Progesterone peaks present in the January–February bleed in the SpayVac group (3a), the 
IVT group (3b), and the 500-μg NWRC group (3c).   July 2000 to February 2006 represents the month and 
years of post-treatment throughout the study. Each data point represents the mean (±SE).
Figure 3a. 
Group1: Pro-
gesterone data 
of SpayVac 
presented as 
μg/ml. 
Figure 3b. 
Group 2: 
Progesterone 
data IVT-PZP 
presented as 
ng/ml.
Figure 3c. 
Group 6: Pro-
gesterone data 
of NWRC 500 
μg presented as 
ng/ml.
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Discussion
This is the fi rst study of a single-injection PZP 
vaccine for white-tailed deer that results in con-
traception rates of 80% for 5 to 7 years. Based on 
the performances of the diff erent vaccine prep-
arations, it is clear that the long-lasting contra-
ceptive eff ect is related to the vaccine design 
and the adjuvant used. The longest contracep-
tive eff ect was achieved in Groups 1 and 2 that 
included PZP produced by IVT and was made 
into an emulsion with the NWRC adjuvant Ad-
juVac. Both of these groups showed periodic 
boosting of the antibody titer, which may be 
central to the long-lasting contraceptive eff ect. 
Because the PZP-contracepted does contin-
ued to cycle throughout the 7-year study, we 
conclude that successful PZP immunocontra-
ception depends on long-lasting, high titers 
of high-affi  nity antibodies and is unlikely the 
result of PZP-immune complexes resulting in 
ovarian damage. 
The immune system is unable to maintain the 
high antibody responses for long periods in the 
absence of a stimulating antigen. Therefore, for 
a successful immunocontraceptive response, 
the antigen must be retained in the immune 
system for months or years (Burton et al. 1994). 
The follicular dendritic cells in the lymph node 
that drains the site of injection may provide 
an answer for the long-term immune response 
found with some antigens. To induce immuno-
contraception that lasts months to years, there 
must be a continued stimulation of these B-cells 
by the injected antigen (Burton et al. 1994).
Antigen preparation 
Diff erences between the methods used to 
harvest oocytes for the IVT and NWRC antigen 
preparations may have aff ected the length of 
contraceptive response. For the NWRC prepa-
ration, the oocytes in the ovaries were cleanly 
released by 2 beds of 500 razor blades, which 
enabled the rapid isolation of oocytes with min-
imal disruption of other ovarian tissue. In con-
trast, for the IVT preparation, the ovaries were 
processed in a meat grinder as the initial step 
for isolating the oocytes. Although most of the 
remaining steps were similar, the initial mate-
rial in the IVT preparation probably contained 
more ovarian tissue. In contrast to the long-term 
effi  cacy achieved with the IVT-PZP groups, the 
NWRC-PZP preparations performed well only 
for 1 to 2 years.
Adjuvants 
The oil-based adjuvant AdjuVac was an im-
portant component of the single-injection vac-
cine, contributing to both the antibody titer 
produced and the long-term contraceptive re-
sponse. The benefi t of AdjuVac was clearly evi-
dent when we compared it to the poor response 
when alum was used as the adjuvant. 
 The liposomes in SpayVac increased the long-
term contraceptive eff ect in other studies and 
species. In this study, the IVT-PZP performed 
almost as well as the SpayVac, although it is 
possible that the addition of AdjuVac dimin-
ished the need for the liposomes in SpayVac. 
Presumably, the liposomes facilitated a signifi -
cant immune response when the vaccine was 
combined with a less-eff ective adjuvant.
Multi-year contraceptive eff ectiveness has oc-
curred in gray seals (Halichoerus grypus; Brown 
et al. 1997), fallow deer (Dama dama; Fraker et 
al. 2002), and white-tailed deer (Odocoileus vir-
ginianus; Locke et al. 2007) as a result of a sin-
gle administration of SpayVac using Freund’s 
Complete Adjuvant. For horses, Liu et al. (2005) 
demonstrated a multiyear contraceptive eff ect 
when PZP was injected with Freund’s adjuvant, 
and Turner et al. (2007) also was able to achieve 
a multiyear contraceptive eff ect with PZP in a 
slow-release microbead. However, in the Liu 
and Turner studies, the contraceptive eff ect 
was limited to 2 years, as we observed with the 
NWRC-PZP prepared by Liu, which is consid-
erably less than the 5–7 years achieved with the 
IVT-PZP in this study.
Emulsion
This study showed that an adjuvant prepared 
with the antigen in the form of an emulsion pro-
vides longer lasting contraception than that ob-
served with a suspension of freeze-dried PZP. 
The antigen administered in a single dose must 
be retained in the body long enough to produce 
specifi c antibodies that will bind with the anti-
gen to form immune complexes (Bachmann et 
al. 1996). It appears that a stiff  emulsion (similar 
to mayonnaise) is important for the retention of 
the intramuscular dose of vaccine.
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The seasonal breeder: endogenous 
PZP antigen results in self-boosting 
It is possible that the success of the PZP-IVT 
vaccines is aff ected by the fact that deer are a 
seasonal multicycling animal. Each season 
when does enter a breeding condition, it is like-
ly that the zona pellucida antigen is presented 
to the immune system, resulting in a self-boost-
ing eff ect. It is possible the particulate nature of 
the IVT-PZP preparations resulted in a longer-
boosting eff ect and contributed to the longer 
contraceptive eff ect. There does not appear to 
be any long-term negative health eff ect from 
the PZP contraception (Miller et al. 2001).
Immunocontraception holds the promise to 
help resolve deer–human confl icts (Bingham 
2007). The possibility of a single-injection PZP 
contraceptive that would be eff ective as a con-
traceptive for multiple years increases the use-
fulness of an injectable contraceptive for the 
reproductive control of wildlife.
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